Press Releases
April 24, 2024
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 16, 2024
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2024
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
March 22, 2024
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 6, 2024
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
January 29, 2024
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 16, 2024
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization